Safety and Tolerability of a Novel Malathion Formulation in Infants and Toddlers With Head Lice - Full Text View

Sponsored by:	Taro Pharmaceuticals USA
Information provided by:	Taro Pharmaceuticals USA
ClinicalTrials.gov Identifier:	NCT00291057

Purpose

In a previous phase II study, the safety and efficacy of a novel formulation of malathion 0.5% was evaluated in patients 2 years of age and older. Based on the results of that study, this formulation is currently in a phase III study for that population.

The current study will use blood markers and clinical evaluations to determine the safety and tolerability of this formulation when used in children 6-24 months of age.

Condition	Intervention	Phase
Lice Infestations	Drug: MALG	Phase II

Drug Information available for: Malathion

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study
Official Title:	Phase II, Multi-Center, Open-Label, Safety and Tolerance Study of a Novel Malathion Formulation in Infants and Toddlers With Pediculosis Capitis

Further study details as provided by Taro Pharmaceuticals USA:

Primary Outcome Measures:

Change in cholinesterase level [ Time Frame: 1 day ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

Clinical evidence of cholinesterase inhibition [ Time Frame: 1 day ] [ Designated as safety issue: Yes ]
Local tolerability [ Time Frame: 1 day ] [ Designated as safety issue: Yes ]
Cure of head lice 14 days after last treatment [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment:	30
Study Start Date:	February 2006
Study Completion Date:	December 2006
Primary Completion Date:	October 2006 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Experimental MALG	Drug: MALG 30 minute application

Eligibility

Ages Eligible for Study:	6 Months to 24 Months
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Confirmed active head lice infestation
Parent or guardian must be able to apply treatment

Exclusion Criteria:

Allergy to pediculicides or hair care products
Scalp conditions other than head lice
Previous head lice treatment within the past 4 weeks
Current antibiotic treatment

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00291057

Locations

United States, Arizona

Scottsdale, Arizona, United States, 85251
United States, Florida

West Palm Beach, Florida, United States, 33409

St. Petersburg, Florida, United States, 33710
United States, New York

New York, New York, United States, 10017
United States, Ohio

Miamiville, Ohio, United States, 45147

Sponsors and Collaborators

Taro Pharmaceuticals USA

Investigators

Principal Investigator:	John Goodman, MD	Hill Top Research
Principal Investigator:	Robert A Lewine, MD	Hill Top Research
Principal Investigator:	Michael Brown, MD	Hill Top Research
Principal Investigator:	Jan Fu, MD, PhD	Hill Top Research
Principal Investigator:	Michael J Alaimo, R.Ph., D.O.	Hill Top Research

More Information

Responsible Party:	Taro Pharmaceuticals USA ( Medical Director )
Study ID Numbers:	MALG-0508
Study First Received:	February 10, 2006
Last Updated:	April 3, 2008
ClinicalTrials.gov Identifier:	NCT00291057
Health Authority:	United States: Food and Drug Administration

Keywords provided by Taro Pharmaceuticals USA:

Pediculosis
Head Lice

Study placed in the following topic categories:

Lice Infestations
Skin Diseases, Infectious
Skin Diseases
Parasitic Diseases
Malathion

Additional relevant MeSH terms:

Ectoparasitic Infestations
Skin Diseases, Parasitic

ClinicalTrials.gov processed this record on January 16, 2009